肾小球滤过率降低的全球心血管与肾脏结局
该研究估算了1990至2013年188个国家肾小球滤过率降低(3、4、5期,未接受肾脏替代治疗)的患病率,并通过汇总随机效应Meta分析计算心血管结局的相对风险。结论认为,到2013年,全球范围内归因于肾小球滤过率降低的心血管死亡数超过终末期肾病死亡数,需要研究评估慢性肾脏病早期检测和治疗对减少这些死亡的益处。
要点
- 在发达和发展中地区,肾小球滤过率降低作为伤残调整生命年风险因素的排名低于高收缩压、高体重指数和高空腹血糖,与高总胆固醇相似。
核心结论
- 到2013年,全球范围内归因于肾小球滤过率降低的心血管死亡数超过终末期肾病死亡数。
- 需要开展研究评估慢性肾脏病早期检测和治疗对减少这些死亡的益处。
研究设计与样本
- 估算了188个国家在1990至2013年六个时间点上肾小球滤过率降低3、4、5期(未接受肾脏替代治疗)的患病率。
- 通过汇总随机效应Meta分析计算了肾小球滤过率降低三个类别心血管结局的相对风险。
主要发现
- 在发达和发展中地区,肾小球滤过率降低作为伤残调整生命年风险因素的排名低于高收缩压、高体重指数和高空腹血糖,与高总胆固醇相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from 1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reduced GFR were calculated by pooled random effects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease, GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95% uncertainty interval [95% UI], 2.0 to 2.4 million). More than half of these attributable deaths were cardiovascular deaths (1.2 million; 95% UI, 1.1 to 1.4 million), whereas 0.96 million (95% UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths.
引用
- Thomas B, Matsushita K, Abate KH, et al. Global Cardiovascular and Renal Outcomes of Reduced GFR. J Am Soc Nephrol. 2017. PMID: 28408440. doi:10.1681/ASN.2016050562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。